@article{JTD21415,
author = {Emilija Nestorovic and Jan D. Schmitto and Sudhir S. Kushwaha and Svetozar Putnik and Dusko Terzic and Natasa Milic and Aleksandar Mikic and Dejan Markovic and Danijela Trifunovic and Arsen Ristic and Miljko Ristic},
title = {Successful establishment of a left ventricular assist device program in an emerging country: one year experience},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {Suppl 15},
year = {2018},
keywords = {},
abstract = {Background: The primary goal of this study was to evaluate the outcomes of patients with end-stage heart failure (HF) who underwent continuous flow left ventricular assist device (CF-LVAD) in a developing country and to compare to those reported by more developed countries. The secondary goal was on determining factors that may be connected to improved survival.
Methods: We prospectively analyzed 47 consecutive patients who underwent CF-LVAD at our institution. After one year the survival and adverse event profiles of patients were evaluated. At 3, 6 and 12 months, the cardiac, renal and liver function outcomes were assessed.
Results: The 30-day, 6-month and 1-year survival rates were 89%, 85% and 80%, respectively. A significant improvement in dimensions and ejection fraction of left ventricle, BNP, functional capacity, blood urea nitrogen (BUN) and total bilirubin (P},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/21415}
}